7.95
-0.135(-1.67%)
Currency In USD
| Previous Close | 8.09 |
| Open | 7.95 |
| Day High | 8.12 |
| Day Low | 7.95 |
| 52-Week High | 17.4 |
| 52-Week Low | 5 |
| Volume | 494 |
| Average Volume | 8,554 |
| Market Cap | 10.02M |
| PE | -0.35 |
| EPS | -23 |
| Moving Average 50 Days | 7.44 |
| Moving Average 200 Days | 8.96 |
| Change | -0.14 |
If you invested $1000 in Sensei Biotherapeutics, Inc. (SNSE) since IPO date, it would be worth $21.03 as of July 16, 2025 at a share price of $7.95. Whereas If you bought $1000 worth of Sensei Biotherapeutics, Inc. (SNSE) shares 3 years ago, it would be worth $198.75 as of July 16, 2025 at a share price of $7.95.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split
GlobeNewswire Inc.
Jun 13, 2025 11:30 AM GMT
BOSTON, June 13, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
GlobeNewswire Inc.
May 06, 2025 11:30 AM GMT
- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutic
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
GlobeNewswire Inc.
Apr 02, 2025 11:30 AM GMT
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John C